Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy
Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Background: Drugs given to treat cancer (chemotherapy) can weaken the human immune system.
But it can also become weaker because of aging. Interleukin (IL)-7, a molecule produced
naturally in the body, can help improve the function of the immune system. Researchers want
to study the effects of IL-7 on immune system function in two different groups of older
people. One group will be people who have received vaccines before IL-7. The other group will
be people who have received Vaccines after IL-7.
Objectives: To evaluate the effect of IL-7 on the immune system responses to vaccines in
older people following chemotherapy.
Eligibility: People at least 60 years of age who have recently finished chemotherapy for
breast, colon, or bladder cancer.
Design:
- People in the study will be screened with a physical examination, medical history, and
blood tests. Other screening tests, such as tumor imaging, may also need to be
performed.
- Everyone will receive a series of five different vaccines commonly used to prevent
diseases. We will compare the responses of people in Sequence 1 who will receive
vaccines before IL-7 with the responses of people in Sequence 2 who received the same
vaccines after IL-7.
- The vaccines will be given randomly in two Arms at different times.
- Arm 1: diphtheria and tetanus, polio, pneumonia (with two booster shots), hepatitis
B (with two booster shots), and hepatitis A (with one booster shot),
- Arm 2: hepatitis A (with one booster shot), hepatitis B (with two booster shots),
pneumococcal (with two booster shots), diphtheria and tetanus, polio, pneumonia
(with two booster shots)
- There are 5 vaccines to be given to each subject, following one of two randomly assigned
sequences of vaccine administration (Sequence 1 or Sequence 2).
- The first vaccine arm contains the two diphtheria protein containing vaccines tetanus
and diphtheria (Td) and pneumococcal conjugate 13 (PCV13) and polio. The second vaccine
arm contains the Hepatitis A and Hepatitis B vaccines. Subjects will either get tetanus,
diphtheria, polio, and pneumonia vaccines before IL-7 therapy (Sequence 1) or hepatitis
A and hepatitis B vaccines before IL-7 therapy (Sequence 2). The response to vaccines
will be evaluated 4 weeks after vaccination. This will be followed by IL-7 therapy, then
administration of the other group of vaccines. Therefore, subjects on both arms will
receive the same set of vaccines, just at different times with respect to IL-7 therapy.